Efficacy of hemopoietic-stimulating factors in patients undergoing chronic hemodialysis

Renal Failure

Volumn 33, Issue 10, 2011, Pages 923-928

  Ziakka, Stavroula ^a   Zagorianakos, Antonios ^a   Koutsovasili, Alexandra ^a   Kaperonis, Nikolaos ^a   Poulikakos, Dimitrios ^a   Sgantzos, Aristeidis ^a   Kolovos, Vasileios ^a   Ntatsis, Giorgos ^a   Papagalanis, Nicolas ^a  

^a RED CROSS HOSPITAL   (Greece)

Author keywords

EPO; Erythropoiesis stimulating factors; ESRF; Hemodialysis; Hemoglobin

Indexed keywords

CONTINUOUS ERYTHROPOIESIS RECEPTOR ACTIVATOR; HEMOGLOBIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN;

ADULT; AGED; ANEMIA; ARTICLE; CLINICAL ARTICLE; FEMALE; HEMODIALYSIS; HEMOGLOBIN BLOOD LEVEL; HUMAN; KIDNEY FAILURE; MALE; PRIORITY JOURNAL;

ADULT; AGED; ANEMIA; FEMALE; HEMATINICS; HEMOGLOBINS; HUMANS; MALE; MIDDLE AGED; RENAL DIALYSIS; RENAL INSUFFICIENCY;

EID: 80054955388     PISSN: 0886022X     EISSN: 15256049     Source Type: Journal    
DOI: 10.3109/0886022X.2011.615963     Document Type: Article

References (16)

1. Yang W, Israni RK, Brunelli SM, Joffe MM, Fishbane S, Feldman HI. Hemoglobin variability and mortality in ESRD. J Am Soc Nephrol. 2007;18:3164-3170. (Pubitemid 350223976)
2. Gilbertson DT, Ebben JP, Foley RN,Weinhandl ED, Bradbury BD, Collins AJ. Hemoglobin level variability: Associations with mortality. Clin J Am Soc Nephrol. 2008;3:133-138.
3. Fishbane S, Berns JS. Hemoglobin cycling in hemodialysis patients treated with recombinant human erythropoietin. Kidney Int. 2005;68:1337-1343. (Pubitemid 43246455)
4. Singh AK, Szczech L, Tang KL, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006;355:2085-2098. (Pubitemid 44749317)
5. Pfeffer MC, Burdmann EA, Chen C-Y, et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med. 2009;361:2019-2032.
6. Solomon SD, Uno H, Lewis EF, et al. Erythropoietic response and outcomes in kidney disease and type 2 diabetes. N Engl J Med. 2010;363:1146-1155.
7. Singh AK. What is causing the mortality in treating the anemia of CKD: EPO dose or Hb level. Curr Opin Nephrol Hypertens. 2010;19:420-424.
8. Keithi-Reddy SR, Addabbo F, Patel T, et al. Associations of anemia and erythropoiesis stimulating agents with inflammatory biomarkers in chronic kidney disease. Kidney Int. 2008;74(6):782-790.
9. Besarab A, Bolton WK, Browne JK, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med. 1998;339:584-590. (Pubitemid 28385655)
10. Regidor D, Kopple J, Kovesdy C, et al. Associations between changes in hemoglobin and administered erythropoeisisstimulating agent and survival in hemodialysis patients. J Am Soc Nephrol. 2006;17:1181-1191.
11. National Kidney Foundation. DOQI clinical practice guidelines for the treatment of Anemia of chronic renal failure. Am J Kidney Dis. 1997;30(Suppl. 3):S194-S240.
12. Unger EF, Thompson AM, Blank MJ, Temple R. Erythropoiesis-stimulating agents - time for a reevaluation. N Eng J Med. 2010;362(3):189-192.
13. Ebben JP, Gilbertson DT, Foley RN, Collins AJ. Hemoglobin level variability: Associations with comorbidity, intercurrent events, and hospitalizations. Clin J Am Soc Nephrol. 2006;1:1205-1210.
14. Lacson Jr., E, Ofsthun N, Lazarus JM. Effect of variability in anemia management on hemoglobin outcomes in ESRD. Am J Kidney Dis. 2003;41:111-124. (Pubitemid 36043358)
15. Harnett J, Kent G, Foley R. Cardiac function and hematocrit level. Am J Kidney Dis. 1995;25(4 Suppl. 1):S3-S7.
16. Winkelmayer W. Against TREATing all patients alike: Lessons from an FDA Advisory CommitteeMeeting. J Am Soc Nephrol. 2011;22:1-2.